press releases

Bioprocessing leader to drive continued commercial development and international expansion Cambridge, UK, and Cambridge, US, 23 March 2026: Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, today announced that it has appointed Dale Gordon as Chair of the Board of Directors. His appointment strengthens governance and board-level expertise at Abselion, adding experienced commercial and bioprocess leadership as the compa

Supports closer engagement with scientists in North America, to meet growing international adoption of its Amperia protein quantification platform Cambridge, UK, and Cambridge, US, 9 March 2026: Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, today announced that it has established a US subsidiary at The Engine in Cambridge, MA. The new location strengthens its presence in the North American life sciences ecosystem, p

Ready-to-use solution, developed in collaboration with GenScript, offers rapid and reliable quantification of His-tagged proteins Broadens Amperia’s applications across recombinant protein research, screening, and development Abselion to showcase kit alongside Amperia platform at PEGS Europe in Lisbon, Portugal from 11–13 November Cambridge, UK, 10 November 2025: Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has ex

New kit enables rapid, accurate titre measurement across broad range of IgG subclasses and species on Amperia platform Cambridge, UK, 22...

Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes Kits incorporate...